The study was designed to analyze the efficacy and safety of Paxlovid for the treatmentof COVID-19.
The study is a real-world study and the case records of patients with COVID-19 who visit
Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid
therapy will be collected in this study. The medical data including patient demographic,
clinical characteristics, laboratory examination, history of treatments, adverse
reactions and treatment outcome will be extracted to analyze the effectivity and safety
of paxlovid and explore the prognosis-relevant factors of COVID-19.
Drug: Paxlovid
The study is a real-world study. According to the actual medical history of patients, the
usage of paxlovid will be collected.
Inclusion Criteria:
- Participants who have a positive SARS-CoV-2 test result;
- Participants who have one or more mild or moderate COVID-19 symptoms.
Exclusion Criteria:
- No specific exclusion criteria in this real world study.
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Investigator: Jiming Zhang, M.D.
Contact: +86 021-52887948
jmzhang@vip.126.com
Feng Sun, MD
+86 02152889999
aaronsf1125@126.com
Feng Sun, MD, Principal Investigator
Huashan Hospital affliatied to Fudan University